2. Search Result
Search Result
Results for "

Histone+deacetylase+inhibitors

" in MedChemExpress (MCE) Product Catalog:

19

Inhibitors & Agonists

8

Peptides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-P2161B
    TAK-683 acetate
    4 Publications Verification

    		 Kisspeptin Receptor Cancer
    TAK-683 acetate is a potent full KISS1 receptor (KISS1R) agonist (IC50=170 pM) with improved metabolic stability. TAK-683 acetate is a nonapeptide metastin analog, exhibits agonistic activities to KISS1R with EC50 values of 0.96 nM and 1.6 nM for human and rat, respectively . TAK-683 acetate depletes GnRH in the hypothalamus and reduces plasma FSH, LH, and testosterone levels in vivo, it has the potential for the study of hormone-dependent prostate cancer .
    TAK-683 acetate
  • HY-P5544
    M-TriDAP

    N-Acetylmuramyl-L-Ala-γ-D-Glu-meso-diaminopimelic acid

    		 NOD-like Receptor (NLR) Others
    M-TriDAP (N-Acetylmuramyl-L-Ala-γ-D-Glu-meso-diaminopimelic acid) is a NOD1/2 agoist and biological active peptide .
    M-TriDAP
  • HY-W014004
    m-Carboxycinnamic acid bishydroxamide

    CBHA

    		 HDAC Apoptosis Others Cancer
    m-Carboxycinnamic acid bishydroxamide (CBHA) is a histone deacetylase inhibitor. m-Carboxycinnamic acid bishydroxamide modulates histone acetylation sites, alters DNA methylation and epigenetic status, increases global histone acetylation, alleviates transcription repression, and facilitates chromatin remodelling. m-Carboxycinnamic acid bishydroxamide can be used for the research of cloned embryo development and epigenetic regulation .
    m-Carboxycinnamic acid bishydroxamide
  • HY-P2161
    TAK-683

    		Kisspeptin Receptor Cancer
    TAK-683 is a potent full KISS1 receptor (KISS1R) agonist (IC50=170 pM) with improved metabolic stability. TAK-683 is a nonapeptide metastin analog, exhibits agonistic activities to KISS1R with EC50 values of 0.96 nM and 1.6 nM for human and rat, respectively . TAK-683 depletes GnRH in the hypothalamus and reduces plasma FSH, LH, and testosterone levels in vivo, it has the potential for the study of hormone-dependent prostate cancer .
    TAK-683
  • HY-118352
    LB-205

    		HDAC Neurological Disease
    LB-205 is a pan-histone deacetylase inhibitor (HDACi). LB-205 can be used for the research of acute traumatic brain injury .
    LB-205
  • HY-W010835
    Boc-D-Cys(Trt)-OH

    Boc-S-trityl-D-cysteine

    		 Amino Acid Derivatives Others
    Boc-D-Cys(Trt)-OH (Boc-S-trityl-D-cysteine) is an amino acid derivative with a Boc protecting group, which can be used to synthesize the bicyclic depsipeptide histone deacetylase inhibitor spirocysteine .
    Boc-D-Cys(Trt)-OH
  • HY-146684
    HDAC-IN-36

    		HDAC Autophagy Apoptosis Cancer
    HDAC-IN-36 (compound 23 g) is an orally active and potent HDAC (histone deacetylase) inhibitor, with an IC50 of 11.68 nM (HDAC6). HDAC-IN-36 promotes apoptosis, autophagy and suppresses migration. HDAC-IN-36 shows anti-tumor and anti-metastatic activity, and can be used for breast cancer research .
    HDAC-IN-36
  • HY-W016689
    2-Amino-4-phenylthiazole

    		Drug Intermediate Cancer
    2-Amino-4-phenylthiazole is a synthetic intermediate useful for pharmaceutical synthesis. 2-Amino-4-phenylthiazole can be used to synthesize suberoylanilide hydroxamic acid (SAHA) analogs with cancer cell growth inhibitory activities. 2-Amino-4-phenylthiazole also can be used to synthesize ketone histone deacetylase inhibitors with antitumor activity in vivo .
    2-Amino-4-phenylthiazole
  • HY-P2115
    Ramorelix

    		GnRH Receptor Cancer
    Ramorelix is a luteinizing-hormone-releasing hormone (LHRH) antagonist. Ramorelix can inhibit tumor progression in vivo. Ramorelix can be studied in anti-cancer research .
    Ramorelix
  • HY-136859
    BATCP

    		HDAC Cancer
    BATCP is a HDAC (Histone deacetylases) inhibitor .
    BATCP
  • HY-139796
    ZYJ-34v

    		HDAC Cancer
    ZYJ-34v is an orally active histone deacetylase inhibitor. ZYJ-34v has antitumor activity .
    ZYJ-34v
  • HY-W339757
    Dioctanoylphosphatidic acid sodium

    		mTOR Endogenous Metabolite Cancer
    Dioctanoylphosphatidic acid sodium functions as a modulator of phagocyte respiratory burst, acts as a precursor to diacylglycerol and lysophosphatidic acid, and influences the phosphorylation of the mammalian target of rapamycin (mTOR) while enhancing the viability of gallbladder carcinoma cells treated with histone deacetylase inhibitors (HDACIs); it is derived from glycerophospholipid through the action of phospholipase D.
    Dioctanoylphosphatidic acid sodium
  • HY-139795
    ZYJ-25e

    		HDAC Cancer
    ZYJ-25e is a potent histone deacetylase inhibitor (HDACi) with IC50s of 0.047 μM and 0.139 μM for HDAC6 and HDAC8, respectively. ZYJ-25e is a tetrahydroisoquinoline-bearing hydroxamic acid analogue. ZYJ-25e shows marked antitumor potency in the MDA-MB231 xenograft model .
    ZYJ-25e
  • HY-116619
    (E/Z)-Dacinostat

    (E/Z)-NVP-LAQ824; (E/Z)-LAQ824

    		 HDAC Apoptosis Others
    (E/Z)-Dacinostat ((E/Z)-NVP-LAQ824) is a histone deacetylase inhibitor that has the ability to induce apoptosis and enhance the activity of fludarabine in killing leukemia cells. (E/Z)-Dacinostat can trigger the production of reactive oxygen species (ROS) and DNA damage, enhance the killing effect of fludarabine on leukemia cells, and induce apoptosis. Its mechanism is related to the regulation of DNA repair processes and intracellular signaling pathways.
    (E/Z)-Dacinostat
  • HY-139815
    ZYJ-34c

    		HDAC Cancer
    ZYJ-34c is an orally active and potent histone deacetylase inhibitor (HDACi) with IC50s of 0.056 μM and 0.146 μM for HDAC6 and HDAC8, respectively. ZYJ-34c causes G1 phase arrest in low concentration. ZYJ-34c has antiproliferative activities. ZYJ-34c exhibits antitumor potency in MDA-MB-231 and HCT116 xenograft models and possesses antimetastatic potential in a mouse hepatoma-22 (H22) pulmonary metastasis model .
    ZYJ-34c
  • HY-P5544A
    M-TriDAP TFA

    N-Acetylmuramyl-L-Ala-γ-D-Glu-meso-diaminopimelic acid TFA

    		 NOD-like Receptor (NLR) Others
    M-TriDAP (N-Acetylmuramyl-L-Ala-γ-D-Glu-meso-diaminopimelic acid) TFA is a NOD1/2 agoist and biological active peptide .
    M-TriDAP TFA
  • HY-P2161A
    TAK-683 TFA

    		Kisspeptin Receptor Cancer
    TAK-683 TFA is a potent full KISS1 receptor (KISS1R) agonist (IC50=170 pM) with improved metabolic stability. TAK-683 TFA is a nonapeptide metastin analog, exhibits agonistic activities to KISS1R with EC50 values of 0.96 nM and 1.6 nM for human and rat, respectively . TAK-683 TFA depletes GnRH in the hypothalamus and reduces plasma FSH, LH, and testosterone levels in vivo, it has the potential for the study of hormone-dependent prostate cancer .
    TAK-683 TFA
  • HY-180343
    FFK29

    		HDAC Infection
    FFK29 is a synthetic class II histone deacetylase inhibitor (HDACi). FFK29 can potently inhibit the growth and encystation of Acanthamoeba. FFK29 can be studied in research on protozoan and parasitic diseases .
    FFK29
  • HY-P11678
    HDAC-IN-100

    		HDAC Apoptosis Caspase Cancer
    HDAC-IN-100 is a histone deacetylase inhibitor with an IC50 of 0.038 μM against HDAC1, 0.283 μM against HDAC2, and 0.586 μM against HDAC3. HDAC-IN-100 acts as a chemosensitizer and apoptosis inducer, activates caspase 3/7, and reverses Cisplatin (HY-17394) resistance. HDAC-IN-100 exerts antiproliferative effects in ovarian cancer cells and squamous cancer cells. HDAC-IN-100 is applicable for research related to ovarian cancer, squamous cell carcinoma, and Cisplatin (HY-17394)-resistant squamous cell carcinoma .
    HDAC-IN-100

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: